Prospective Multicenter Randomized Intermediate Biomarker Study of Oral Contraceptive versus Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch Syndrome

Departments of 1Gynecologic Oncology and Reproductive Medicine, 2Biostatistics, 3Clinical Cancer Genetics Program, and 4Pathology, The University of Texas MD Anderson Cancer Center; 5Department of Integrative Biology and Pharmacology, The University of Texas Health Science Center, Houston, Texas; Departments of 6Gynecologic Oncology and 7Medicine, The University of California San Francisco, San Francisco, California; 8Department of Preventative Medicine, Creighton University, Omaha, Nebraska; and 9Department of Gynecologic Oncology, Johns Hopkins University, Baltimore, Maryland

Departments of 1Gynecologic Oncology and Reproductive Medicine, 2Biostatistics, 3Clinical Cancer Genetics Program, and 4Pathology, The University of Texas MD Anderson Cancer Center; 5Department of Integrative Biology and Pharmacology, The University of Texas Health Science Center, Houston, Texas; Departments of 6Gynecologic Oncology and 7Medicine, The University of California San Francisco, San Francisco, California; 8Department of Preventative Medicine, Creighton University, Omaha, Nebraska; and 9Department of Gynecologic Oncology, Johns Hopkins University, Baltimore, Maryland

Departments of 1Gynecologic Oncology and Reproductive Medicine, 2Biostatistics, 3Clinical Cancer Genetics Program, and 4Pathology, The University of Texas MD Anderson Cancer Center; 5Department of Integrative Biology and Pharmacology, The University of Texas Health Science Center, Houston, Texas; Departments of 6Gynecologic Oncology and 7Medicine, The University of California San Francisco, San Francisco, California; 8Department of Preventative Medicine, Creighton University, Omaha, Nebraska; and 9Department of Gynecologic Oncology, Johns Hopkins University, Baltimore, Maryland

Departments of 1Gynecologic Oncology and Reproductive Medicine, 2Biostatistics, 3Clinical Cancer Genetics Program, and 4Pathology, The University of Texas MD Anderson Cancer Center; 5Department of Integrative Biology and Pharmacology, The University of Texas Health Science Center, Houston, Texas; Departments of 6Gynecologic Oncology and 7Medicine, The University of California San Francisco, San Francisco, California; 8Department of Preventative Medicine, Creighton University, Omaha, Nebraska; and 9Department of Gynecologic Oncology, Johns Hopkins University, Baltimore, Maryland

Departments of 1Gynecologic Oncology and Reproductive Medicine, 2Biostatistics, 3Clinical Cancer Genetics Program, and 4Pathology, The University of Texas MD Anderson Cancer Center; 5Department of Integrative Biology and Pharmacology, The University of Texas Health Science Center, Houston, Texas; Departments of 6Gynecologic Oncology and 7Medicine, The University of California San Francisco, San Francisco, California; 8Department of Preventative Medicine, Creighton University, Omaha, Nebraska; and 9Department of Gynecologic Oncology, Johns Hopkins University, Baltimore, Maryland

Departments of 1Gynecologic Oncology and Reproductive Medicine, 2Biostatistics, 3Clinical Cancer Genetics Program, and 4Pathology, The University of Texas MD Anderson Cancer Center; 5Department of Integrative Biology and Pharmacology, The University of Texas Health Science Center, Houston, Texas; Departments of 6Gynecologic Oncology and 7Medicine, The University of California San Francisco, San Francisco, California; 8Department of Preventative Medicine, Creighton University, Omaha, Nebraska; and 9Department of Gynecologic Oncology, Johns Hopkins University, Baltimore, Maryland

Departments of 1Gynecologic Oncology and Reproductive Medicine, 2Biostatistics, 3Clinical Cancer Genetics Program, and 4Pathology, The University of Texas MD Anderson Cancer Center; 5Department of Integrative Biology and Pharmacology, The University of Texas Health Science Center, Houston, Texas; Departments of 6Gynecologic Oncology and 7Medicine, The University of California San Francisco, San Francisco, California; 8Department of Preventative Medicine, Creighton University, Omaha, Nebraska; and 9Department of Gynecologic Oncology, Johns Hopkins University, Baltimore, Maryland

Departments of 1Gynecologic Oncology and Reproductive Medicine, 2Biostatistics, 3Clinical Cancer Genetics Program, and 4Pathology, The University of Texas MD Anderson Cancer Center; 5Department of Integrative Biology and Pharmacology, The University of Texas Health Science Center, Houston, Texas; Departments of 6Gynecologic Oncology and 7Medicine, The University of California San Francisco, San Francisco, California; 8Department of Preventative Medicine, Creighton University, Omaha, Nebraska; and 9Department of Gynecologic Oncology, Johns Hopkins University, Baltimore, Maryland

Departments of 1Gynecologic Oncology and Reproductive Medicine, 2Biostatistics, 3Clinical Cancer Genetics Program, and 4Pathology, The University of Texas MD Anderson Cancer Center; 5Department of Integrative Biology and Pharmacology, The University of Texas Health Science Center, Houston, Texas; Departments of 6Gynecologic Oncology and 7Medicine, The University of California San Francisco, San Francisco, California; 8Department of Preventative Medicine, Creighton University, Omaha, Nebraska; and 9Department of Gynecologic Oncology, Johns Hopkins University, Baltimore, Maryland

Departments of 1Gynecologic Oncology and Reproductive Medicine, 2Biostatistics, 3Clinical Cancer Genetics Program, and 4Pathology, The University of Texas MD Anderson Cancer Center; 5Department of Integrative Biology and Pharmacology, The University of Texas Health Science Center, Houston, Texas; Departments of 6Gynecologic Oncology and 7Medicine, The University of California San Francisco, San Francisco, California; 8Department of Preventative Medicine, Creighton University, Omaha, Nebraska; and 9Department of Gynecologic Oncology, Johns Hopkins University, Baltimore, Maryland

Departments of 1Gynecologic Oncology and Reproductive Medicine, 2Biostatistics, 3Clinical Cancer Genetics Program, and 4Pathology, The University of Texas MD Anderson Cancer Center; 5Department of Integrative Biology and Pharmacology, The University of Texas Health Science Center, Houston, Texas; Departments of 6Gynecologic Oncology and 7Medicine, The University of California San Francisco, San Francisco, California; 8Department of Preventative Medicine, Creighton University, Omaha, Nebraska; and 9Department of Gynecologic Oncology, Johns Hopkins University, Baltimore, Maryland

Departments of 1Gynecologic Oncology and Reproductive Medicine, 2Biostatistics, 3Clinical Cancer Genetics Program, and 4Pathology, The University of Texas MD Anderson Cancer Center; 5Department of Integrative Biology and Pharmacology, The University of Texas Health Science Center, Houston, Texas; Departments of 6Gynecologic Oncology and 7Medicine, The University of California San Francisco, San Francisco, California; 8Department of Preventative Medicine, Creighton University, Omaha, Nebraska; and 9Department of Gynecologic Oncology, Johns Hopkins University, Baltimore, Maryland

Departments of 1Gynecologic Oncology and Reproductive Medicine, 2Biostatistics, 3Clinical Cancer Genetics Program, and 4Pathology, The University of Texas MD Anderson Cancer Center; 5Department of Integrative Biology and Pharmacology, The University of Texas Health Science Center, Houston, Texas; Departments of 6Gynecologic Oncology and 7Medicine, The University of California San Francisco, San Francisco, California; 8Department of Preventative Medicine, Creighton University, Omaha, Nebraska; and 9Department of Gynecologic Oncology, Johns Hopkins University, Baltimore, Maryland

Departments of 1Gynecologic Oncology and Reproductive Medicine, 2Biostatistics, 3Clinical Cancer Genetics Program, and 4Pathology, The University of Texas MD Anderson Cancer Center; 5Department of Integrative Biology and Pharmacology, The University of Texas Health Science Center, Houston, Texas; Departments of 6Gynecologic Oncology and 7Medicine, The University of California San Francisco, San Francisco, California; 8Department of Preventative Medicine, Creighton University, Omaha, Nebraska; and 9Department of Gynecologic Oncology, Johns Hopkins University, Baltimore, Maryland

Departments of 1Gynecologic Oncology and Reproductive Medicine, 2Biostatistics, 3Clinical Cancer Genetics Program, and 4Pathology, The University of Texas MD Anderson Cancer Center; 5Department of Integrative Biology and Pharmacology, The University of Texas Health Science Center, Houston, Texas; Departments of 6Gynecologic Oncology and 7Medicine, The University of California San Francisco, San Francisco, California; 8Department of Preventative Medicine, Creighton University, Omaha, Nebraska; and 9Department of Gynecologic Oncology, Johns Hopkins University, Baltimore, Maryland

Departments of 1Gynecologic Oncology and Reproductive Medicine, 2Biostatistics, 3Clinical Cancer Genetics Program, and 4Pathology, The University of Texas MD Anderson Cancer Center; 5Department of Integrative Biology and Pharmacology, The University of Texas Health Science Center, Houston, Texas; Departments of 6Gynecologic Oncology and 7Medicine, The University of California San Francisco, San Francisco, California; 8Department of Preventative Medicine, Creighton University, Omaha, Nebraska; and 9Department of Gynecologic Oncology, Johns Hopkins University, Baltimore, Maryland